Zydus Cadila has received final approval for Piroxicam Capsules USP in the strengths of 10 mg and 20 mg, from the US health regulator.

This capsules are used for treatment of osteoarthritis and rheumatoid arthritis and it will be produced at the group’s manufacturing facility at SEZ, Ahmedabad. Moreover, the group has more than 209 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.

Read EquityPandit’s Technical Analysis of Nifty Pharma